Scholarlink

Background <p>Xanthophylls, a subclass of oxygenated carotenoids, are highly valued for their wide range of applications in the food and pharmaceutical industries, particularly due to their antioxidant properties and potential health benefits. Among these, neoxanthin, a less studied xanthophyll, has demonstrated significant therapeutic potential, including antioxidant and anticancer activities. Neoxanthin is also the primary precursor for the synthesis of other valuable compounds, such as fucoxanthin and β-damascenone, which are important in the cosmetic and pharmaceutical sectors.</p> Results <p>In this study, we report the first heterologous production of neoxanthin in <i>Saccharomyces cerevisiae</i> through a combination of metabolic and enzyme engineering. First, a <i>S. cerevisiae</i> strain was engineered to produce neoxanthin by expressing genes from the β-carotene and violaxanthin biosynthesis pathways. Following this, the VDL1 gene from <i>Phaeodactylum tricornutum</i>, responsible for converting violaxanthin into neoxanthin, was expressed, resulting in the production of 0.18&#xa0;mg/g<sub>DCW</sub> of neoxanthin. To further enhance production, a pulse-fed galactose strategy was employed during shake-flask growth, leading to a 2.5-fold increase in neoxanthin yield. Additionally, transmembrane peptides were incorporated into the yeast cells to improve the accumulation of carotenoids, generating an increase of 3.8-fold, achieving a final production of 0.7&#xa0;mg/g<sub>DCW</sub> of neoxanthin.</p> Conclusions <p>This is the highest reported yield of neoxanthin produced by engineered microorganisms, and the strategies employed here have considerable potential for scaling up production of this carotenoid.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic engineering of Saccharomyces cerevisiae for neoxanthin production

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月1日

查看全文
  • Natalia Arenas,
  • Vicente F. Cataldo,
  • Eduardo Agosin

摘要

Background

Xanthophylls, a subclass of oxygenated carotenoids, are highly valued for their wide range of applications in the food and pharmaceutical industries, particularly due to their antioxidant properties and potential health benefits. Among these, neoxanthin, a less studied xanthophyll, has demonstrated significant therapeutic potential, including antioxidant and anticancer activities. Neoxanthin is also the primary precursor for the synthesis of other valuable compounds, such as fucoxanthin and β-damascenone, which are important in the cosmetic and pharmaceutical sectors.

Results

In this study, we report the first heterologous production of neoxanthin in Saccharomyces cerevisiae through a combination of metabolic and enzyme engineering. First, a S. cerevisiae strain was engineered to produce neoxanthin by expressing genes from the β-carotene and violaxanthin biosynthesis pathways. Following this, the VDL1 gene from Phaeodactylum tricornutum, responsible for converting violaxanthin into neoxanthin, was expressed, resulting in the production of 0.18 mg/gDCW of neoxanthin. To further enhance production, a pulse-fed galactose strategy was employed during shake-flask growth, leading to a 2.5-fold increase in neoxanthin yield. Additionally, transmembrane peptides were incorporated into the yeast cells to improve the accumulation of carotenoids, generating an increase of 3.8-fold, achieving a final production of 0.7 mg/gDCW of neoxanthin.

Conclusions

This is the highest reported yield of neoxanthin produced by engineered microorganisms, and the strategies employed here have considerable potential for scaling up production of this carotenoid.